Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain and Antiviral Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AAK1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase | AAK1 Kinase Domain (Active) High purity (>95%), Sequence Verified, ATP-binding validated. Theoretical MW confirmed. |
View AAK1 Products |
| Full-Length Protein | AAK1 Full-Length Recombinant Protein HEK293 Expressed, Native folding, Endotoxin <1EU/µg. |
View AAK1 Products |
| Gene Delivery | AAK1 Lentivirus Premade Particles Full-length ORF for stable Ba/F3 or HEK293T cell line construction. |
View AAK1 Products |
| Benchmark Antibody | Anti-AAK1 (Clone for Vertex VX-150 Development) Recombinant rabbit monoclonal, Phospho-specific option available. |
View AAK1 Products |
| RNAi Validator | AAK1 siRNA Set (3 unique sequences) For target specificity verification in cellular assays. |
View AAK1 Products |
| Substrate Protein | AP2M1 (Mu2 subunit of AP2) Native substrate for AAK1 kinase assays, Unphosphorylated form. |
View AP2M1 Products |
| Selectivity Panel | BMP2K (AAK2) Active Kinase NAK family homolog for cross-reactivity screening, >95% purity. |
View BMP2K Products |
| Selectivity Panel | BIKE (NAK) Active Kinase Related BMP2K kinase for kinome selectivity profiling. |
View BIKE Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NAK Family Selectivity (AAK1 vs BMP2K vs BIKE) | Purified active kinases with verified ATP-binding affinity (Kd measured by SPR). Sequence-verified catalytic domains ensure accurate selectivity ratios. |
| Substrate Phosphorylation Validation | Unphosphorylated AP2M1 substrate protein available; TR-FRET compatible format. Endotoxin-controlled for cellular phosphorylation assays. |
| Blood-Brain Barrier Permeability Screening | AAK1 Lentivirus for stable hCMEC/D3 cell line construction; tight junction integrity compatible. |
| Gatekeeper Resistance Mutations | AAK1 T gatekeeper mutant recombinant protein available for resistance mechanism studies. |
| Cellular Target Engagement | Validated siRNA set for knockdown confirmation; biosimilar anti-AAK1 antibody for Western/IP. |
Live AAK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AAK1 therapeutics has shifted following the discontinuation of first-generation inhibitors (Vertex's VX-150 and Lilly's LY3526318) in Phase 1/2 pain studies. Current R&D momentum is pivoting toward antiviral applications (SARS-CoV-2 and Ebola virus entry inhibition) and next-generation CNS-penetrant kinase inhibitors with improved NAK-family selectivity profiles. As the field recognizes AAK1's scaffolding functions beyond catalytic activity, drug discovery programs are increasingly requiring full-length protein formats and cellular context assays to differentiate catalytic inhibition from protein-protein disruption.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Vertex (discontinued), Lilly (discontinued), academic consortiums | Neuropathic Pain, Acute Pain | NAK Family Selectivity Panel (Need active AAK1, BMP2K, BIKE with verified kinetics) |
| Antiviral Entry Inhibitor | NIH, Scripps Research | SARS-CoV-2, Ebola, Viral Infections | Endocytosis Assay (Need full-length AAK1 Lentivirus for stable cell lines) |
| PROTAC Degrader | Emerging biotech | Oncology (endocytosis modulation) | Ternary Complex Formation (Need full-length protein, not just kinase domain) |
| Allosteric Modulator | Preclinical programs | Neurodegeneration | Conformational Assay (Need mutant constructs for binding site verification) |